secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0000950170-24-121456
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q3 revenue $45.1M (+11%), net loss improves to ($15.4M), launches Nanoplasty MIS system
--------------------------------------------------------------------------------

- Revenue $45.1M (+11% YoY); net loss improved to ($15.4M) or ($0.25)/share from ($17.5M) loss in Q3 2023.
- Adjusted EBITDA loss narrowed 45% to ($5.1M) from ($9.2M) in Q3 2023.
- First entry into osteotomy market with Nanoplasty 3D Minimally Invasive Bunion Correction system; second MIS platform planned later in Q4.
- Filed patent infringement suit to protect Lapiplasty technology; patent portfolio now 67 U.S. patents.
- FY2024 revenue guidance revised to $204M-$211M (was $201M-$211M); expects Adjusted EBITDA loss to halve YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024121456/0000950170-24-121456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024121456/tmci-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer